The Centers for Disease Control and Prevention and Food and Drug Administration are investigating a multistate outbreak of salmonella linked to products reported to contain kratom, a plant consumed for its stimulant effects and as an opioid substitute. According to CDC, 28 people in 20 states have been infected since mid-October, 11 of whom were hospitalized. No common brands or suppliers of kratom have been identified. The agencies are advising consumers to avoid kratom and kratom-containing products. “In addition to the public health concerns raised by this outbreak, kratom affects the same opioid brain receptors as morphine and appears to have properties that expose people who consume kratom to the risks of addiction, abuse and dependence,” FDA said. In other news, FDA today announced the voluntary destruction and recall of kratom-containing dietary supplements made by Divinity Products Distribution. The agency is not aware of recent reports of illness associated with the Divinity products, but asks health care professionals to report any adverse events involving kratom products to its Safety Reporting Portal.
 

Related News Articles

Headline
The House Committee on Oversight and Reform today held the third in a series of hearings examining solutions to the opioid epidemic, which focused on the…
Headline
The Centers for Disease Control and Prevention this week announced an anticipated shortage of Aplisol, one of two TB skin tests licensed by the Food and Drug…
Headline
The Food and Drug Administration today published a notice seeking comment through July 30 on a potential change to the Opioid Analgesic Risk Evaluation and…
Headline
A federal court in Texas yesterday ordered Pharm D Solutions to stop producing or distributing compounded drugs intended to be sterile until the company…
Headline
The Health Resources and Services Administration yesterday awarded 120 organizations, including hospitals, $200,000 each to develop community partnerships and…
Headline
The Food and Drug Administration Friday issued final guidance clarifying how sponsors may show that a proposed biosimilar product is interchangeable with a…